Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
October 01, 2016 03:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
September 28, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Licenses DRM04 to Maruho for Hyperhidrosis in Japan
September 20, 2016 16:05 ET
|
Dermira, Inc.
Terms include $25 million upfront license payment to DermiraMaruho to fund all development and commercial costs for DRM04 in Japan MENLO PARK, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) --...
Dermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from Takeda
September 12, 2016 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...